Should I Buy CC? CC 2026 Analysis

Should You Buy Chemours Co (CC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

18.320

1 Day change

8.47%

52 Week Range

18.470

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now at ~$16.5: price is sitting on/just below near-term resistance (R1 ~16.50) with momentum looking stretched.
Technical setup is bullish longer-term (stacked moving averages), but short-term is overbought (RSI>70) and MACD is still below zero—risk of a pullback is elevated.
Options positioning is strongly call-skewed (bullish sentiment), but implied volatility is high, suggesting the market is pricing meaningful near-term moves.
Analyst tone has improved recently (multiple target raises), which supports a medium-term recovery case; however, the latest reported quarter (2025/Q3) showed clear earnings/margin deterioration.
No politician/congress trading signal is available to add conviction.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bullish structure via moving averages (SMA_5 > SMA_20 > SMA_200), indicating an improving intermediate trend.
Momentum: MACD histogram -0.0184 (below 0) but negatively contracting → bearish momentum is fading, yet not fully flipped bullish.
RSI: RSI_6 = 73.83 → effectively overbought; increases odds of near-term digestion/pullback.
Key levels: Pivot 15.618 (important support/line in the sand). Immediate resistance R1 16.501 (price ~16.5 is pressing this), next R2 17.046. Supports: S1 14.736, S2 14.191.
Pattern-probability signal: Similar-pattern stats imply modest next-day upside (+0.67%) but weaker next-week expectation (-1.72%), aligning with “near-term stretched” conditions.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/call open interest ratio 0.38 and put/call volume ratio 0.06 → very call-heavy positioning (bullish/optimistic sentiment).
Activity: Today’s option volume vs 30-day avg ~120.9% → elevated participation.
Volatility: 30D IV ~73.93 vs historical vol ~63.84; IV percentile 78.4 → options are expensive and the market is pricing larger swings.
Takeaway: Positioning is supportive, but elevated IV often coincides with event-risk pricing and can amplify drawdowns if price stalls at resistance.

Technical Summary

Sell

Buy

Positive Catalysts

- Recent Taiwan TiO2 site sale ($360M) improves liquidity and supports potential debt reduction (viewed positively by analysts).
- Multiple Street target raises in January 2026 reinforce improving sentiment.
- Potential tailwind cited by analysts: longer-cycle demand for low-GWP refrigerants (HFOs) over the next 10–20 years.
- Upcoming earnings: QDEC 2025 earnings on 2026-02-17 (After Hours) could reset expectations if results/guide improve.

Neutral/Negative Catalysts

- Near-term technical risk: RSI overbought and price pressed against resistance (~16.50), increasing pullback odds.
- Macro/industry: “Low-growth” demand backdrop and slow demand in Europe/Asia cited as headwinds.
- Business pressure: TiO2 pricing pressure and operational issues in Advanced Performance Materials (per prior analyst commentary).
- Legal/overhang risk: PFAS settlement uncertainty remains a key investor concern.
- High implied volatility suggests the market is bracing for meaningful moves, which can work against new long entries if price fails to break resistance.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $1.495B, down -0.86% YoY (slight top-line contraction).
Profitability: Net income $60M, down -287.50% YoY; EPS $0.40, down -290.48% YoY (sharp earnings deterioration).
Margins: Gross margin 15.72%, down -17.39% YoY (margin compression trend is negative).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend (Jan 2026): Tone improved with multiple price target raises and bullish ratings maintained:
- Truist (2026-01-21): PT to $21 from $18, Buy.
- BMO (2026-01-19): PT to $20 from $18, Outperform (Taiwan TiO2 sale viewed as meaningful positive).
- RBC (2026-01-16): PT to $18 from $16, Outperform.
Prior mixed/softer actions (late 2025):
- JPMorgan (2025-12-03): PT cut to $13 from $15, Neutral.
- UBS (2025-11-11): PT cut to $18 from $21, Buy.
- RBC (2025-11-10): PT cut to $17 from $19, Outperform.
- Mizuho (2025-11-07): PT cut to $14 from $18, Outperform.
Wall Street pros/cons view:
- Pros: Asset sale proceeds bolster balance sheet flexibility; analysts see pathways to improved TiO2 margins and structural refrigerant demand.
- Cons: Near-term demand remains constrained; recent quarter showed margin/earnings deterioration; PFAS liability remains an overhang.

7 Analyst Rating

Wall Street analysts forecast CC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CC is 16.14 USD with a low forecast of 13 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 16.890

Low

Averages

16.14

High

Current: 16.890

Low

Averages

16.14

High

Truist

Buy

maintain

$18 -> $21

AI Analysis

2026-01-21

Reason

Truist

Price Target

$18 -> $21

AI Analysis

2026-01-21

maintain

Buy

Reason

Truist raised the firm's price target on Chemours to $21 from $18 and keeps a Buy rating on the shares. The firm adjusted targets in the chemicals group as part of its Q4 earnings preview. The analyst says demand growth for the group will be limited in 2026 given the "low-growth" macro environment. Truist expects relative strength to continue for the companies with exposure to AI and data centers.

BMO Capital

John McNulty

Outperform

maintain

$18 -> $20

2026-01-19

Reason

BMO Capital

John McNulty

Price Target

$18 -> $20

2026-01-19

maintain

Outperform

Reason

BMO Capital analyst John McNulty raised the firm's price target on Chemours to $20 from $18 and keeps an Outperform rating on the shares after the company sold its Taiwan TiO2 site for $360M. The "sizable windfall" is a "meaningful positive" for Chemours, the analyst tells investors in a research note. BMO expects the proceeds to go toward debt reduction, providing a "liquidity cushion" for future PFAS settlements. The firm says the sale should help investors "get comfortable" that Chemours has enough cash to fund future growth opportunities going forward.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CC

Unlock Now

CC Should I Buy

CC Should I Buy

Should You Buy Chemours Co (CC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch